source
- RallyBio pursues second reverse merger, this time with cancer drug developer Avenzo TherapeuticsRallyBio announced on Monday that it will merge with cancer-focused Avenzo Therapeutics in a reverse‑merger transaction. The combined entity will operate under the Avenzo Therapeutics name. The de…
- #ASCO26: Lilly's plenaries; Incyte's frontline data in lymphomaTwo plenaries related to Lilly: Researchers detailed findings from an investigator-sponsored trial using Lilly’s CDK4/6 inhibitor Verzenio in a rare cancer called dedifferentiated liposarcoma, show…